Two different dosing regimens demonstrated efficacy with one showing a better profile; No hospitalisations or severe cases of COVID-19 in participants treated with AZD1222
Today marks an important step in turning the corner on the pandemic and getting things back to normal. Following the positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil, which showed the vaccine was highly effective in preventing COVID-19, we are confident that our united response, across the scientific community, industry, organisations, and governments, will make significant inroads in curbing the COVID-19 pandemic that has continued to claim thousands of lives every day in Africa and across the globe. We will continue to work hard to honour our commitment to make the vaccine available in a fair and equitable manner as rapidly as possible, following robust regulatory approval and meeting stringent efficacy and safety standards. It is a great day for innovation and for inclusion, an exciting moment for human health.
Barbara Nel Country President African Cluster: South Africa, Sub Saharan Africa, French Speaking Africa
Full AstraZeneca Regulatory News Service News Release available here (bit.ly/339VrKS).
Distributed by APO Group on behalf of AstraZeneca.